Cytochrome P-450 and the response to antimalarial drugs;El citocromo P-450 y la respuesta terapéutica a los antimaláricos

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 19, Issue 1, 2006, Pages 9-22

  Guzmán, Valentina ^a,b   Carmona Fonseca, Jaime ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b Laboratorio 610   (Colombia)

Author keywords

Antimalarials; Cytochrome P 450 enzyme system; Malaria; Plasmodium falciparum

Indexed keywords

AMINOPYRINE N DEMETHYLASE; AMODIAQUINE; ANTIMALARIAL AGENT; ASCORBIC ACID; CAFFEINE; CHLOROQUINE; CYTOCHROME P450; CYTOCHROME P450 2E1; CYTOCHROME P450 3A2; ETHYLMORPHINE; GLUCURONOSYLTRANSFERASE; HALOFANTRINE; ICOSANOID; LIDOCAINE; MEFLOQUINE; METRONIDAZOLE; NICOTINIC ACID; PARACETAMOL; PHENAZONE; PROGUANIL; PYRIMETHAMINE; QUININE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; RETINOL; RIBOFLAVIN; STEROID; SULFADOXINE; UNINDEXED DRUG; UNSPECIFIC MONOOXYGENASE; XENOBIOTIC AGENT;

ANTIMALARIAL AGENT; CYTOCHROME; DRUG; ENZYME ACTIVITY; GENETICS; PHENOTYPE; RESEARCH WORK;

ABDOMINAL PAIN; ALLELE; DATA BASE; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; GENE MUTATION; GENETIC VARIABILITY; HEREDITY; HUMAN; INFECTION; INFLAMMATION; LIVER DISEASE; MALARIA; MAXIMUM ALLOWABLE CONCENTRATION; MEDICAL RESEARCH; NAUSEA; NONHUMAN; NUTRITIONAL STATUS; PHENOTYPE; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VOMITING; ADULT; ANIMAL; BIOTRANSFORMATION; CHILD; COMPARATIVE STUDY; DISEASE MODEL; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MALARIA FALCIPARUM; METABOLISM; MOUSE; MURINAE; MUTATION; ORAL DRUG ADMINISTRATION; PLASMODIUM BERGHEI; RAT;

HEPATICA;

ADMINISTRATION, ORAL; ADULT; AMODIAQUINE; ANIMALS; ANTIMALARIALS; BIOTRANSFORMATION; CHILD; CHLOROGUANIDE; CHLOROQUINE; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES; DISEASE MODELS, ANIMAL; GENOTYPE; HUMANS; MALARIA; MALARIA, FALCIPARUM; MEFLOQUINE; MICE; MURINAE; MUTATION; NUTRITIONAL STATUS; PHENOTYPE; PLASMODIUM BERGHEI; POLYMORPHISM, GENETIC; RATS;

EID: 33645580752     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/s1020-49892006000100003     Document Type: Review

References (110)

1. Organización Panamericana de la Salud. Evaluación de la eficacia terapéutica de los medicamentos para el tratamiento del paludismo por Plasmodium falciparum sin complicaciones en las Américas. Washington, D.C.: OPS; 1998. (OPS/HCP/HCT/113/98).
2. World Health Organization, Roll Back Malaria. The use of antimalarial drugs. Report of a WHO informal consultation. Geneva: WHO; 2001. (WHO/CDS/RBM/2001.33).
3. Blair S, Lacharme L, Carmona J, Tobon A. Resistencia de Plasmodium falciparum a los antimaláricos en Urabá y Bajo Cauca Antioqueño, 1998. Rev Epid Antioq. 1999;24:3-4.
4. Blair S, Lacharme LL, Fonseca JC, Tobon A. Resistencia de Plasmodium falciparum a tres antimaláricos en Turbo (Antioquia, Colombia), 1998. Rev Panam Salud Publica. 2001;9(1):23-9.
5. Bloland PB. Drug resistance in malaria. Chamblee, Georgia: World Health Organization; 2001. (WHO/CDS/CSR/DRS/2001.4).
6. Ter Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 1995;89(6):660-4.
7. Hess FI, Iannuzzi A, Leafasia J, Cowdrey D, Nothdurft HD, von Sonnenburg F, et al. Risk factors of chloroquine resistance in Plasmodium falciparum malaria. Acta Trop. 1996;61(4):293-306.
8. Fontanet AL, Walker AM. Predictors of treatment failure in multiple drug-resistant falciparum malaria: results from a 42-day follow-up of 224 patients in eastern Thailand. Am J Trop Med Hyg. 1993;49(4):465-72.
9. Olanrewaju WI, Johnson AW. Chloroquine-resistant Plasmodium falciparum malaria in Ilorin, Nigeria: prevalence and risk factors for treatment failure. Afr J Med Med Sci. 2001;30(3):165-9.
10. Sowunmi A, Fateye BA, Happi TC, Gbotosho GO, Oduola AM. Plasmodium falciparum gametocytaemia in Nigerian children: Peripheral immature gametocytaemia as an indicator of a poor response to chloroquine treatment, and its relationship to molecular determinants of chloroquine resistance. Ann Trop Med Parasitol. 2003;97(5):453-68.
11. Arango E, Álvarez T, Carmona J, Blair S. Gametocitemia de Plasmodium falciparum según la respuesta terapéutica a sulfadoxinapirimetamina y cloroquina en dos municipios de Antioquia, Colombia. Biomedica. 2004;24(1):79-88.
12. Blair S, Carmona J, Correa A. Malaria en niños: relación entre nutrición e inmunidad. Rev Panam Salud Publica. 2002;11(1):5-14.
13. Hillier K. Drug interaction with oral contraceptives. Fertil Contracept. 1978;2(1):5-8.
14. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54(10):1271-94.
15. Werck-Reichhart D, Feyereisen R. Cytochromes P-450: a success story. Genome Biol. 2000;1(6):3003.1-9.
16. Benet L, Kroetz D, Sheiner L. Dinámica de la absorción, distribución y eliminación de los fármacos. En: Hardman JG, Limbird LE, Gilman AG, eds. Las bases farmacológicas de la terapéutica de Goodman y Gilman. México, D.F.: McGraw-Hill Interamericana; 2003. Pp. 3-19.
17. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40(5):343-73.
18. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003;59(5-6):429-42.
19. Walker O, Birkett DJ, Alvan G, Gustafsson LL, Sjoqvist F. Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol. 1983;15(3):375-7.
20. Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31(6):748-54.
21. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002;300(2):399-407.
22. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet. 1996;30(4): 263-99.
23. Karbwang J, Na-Bangchang K. Clinical application of mefloquine pharmacokinetics in the treatment of P. falciparum malaria. Fundam Clin Pharmacol. 1994;8(6):491-502.
24. Lu AH, Shu Y, Huang SL, Wang W, Ou-Yang DS, Zhou HH. In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin. 2000;21(8):747-52.
25. Edstein MD, Veenendaal JR, Scott HV, Rieckmann KH. Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. Chemotherapy. 1988;34(5):385-92.
26. República de Colombia, Ministerio de Salud, Dirección General de Promoción y Prevención. Guía de atención clínica para el diagnóstico y tratamiento de la malaria. Santa Fe de Bogotá: Ministerio de Salud de Colombia; 1999.
27. Walker O, Dawodu AH, Salako LA, Alvan G, Johnson AO. Single dose disposition of chloroquine in kwashiorkor and normal children: evidence for decreased absorption in kwashiorkor. Br J Clin Pharmacol. 1987;23(4):467-72.
28. Tulpule A, Krishnaswamy K. Chloroquine kinetics in the undernourished. Eur J Clin Pharmacol. 1983;24(2):273-6.
29. Fontaine F, de Sousa G, Burcham PC, Duchene P, Rahmani R. Role of cytochrome P-450 3A in the metabolism of mefloquine in human and animal hepatocytes. Life Sci. 2000;66(22):2193-212.
30. Kaneko A, Kaneko O, Taleo G, Bjorkman A, Kobayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet. 1997;349(9056):921-2.
31. Hamedi Y, Nateghpour M, Tan-ariya P, Tiensuwan M, Silachamroon U, Looareesuwan S. Plasmodium vivax malaria in Southeast Iran in 1999-2001: establishing the response to chloroquine in vitro and in vivo. Southeast Asian J Trop Med Public Health. 2002;33(3): 512-8.
32. Cutler DJ. Possible mechanisms of action of antimalarials in rheumatic disease. Agents Actions Suppl. 1993;44:139-43.
33. Basco LK, Same-Ekobo A, Ngane VF, Ndounga M, Metoh T, Ringwald P, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ. 2002; 80(7):538-45.
34. López YL, Salazar A. Evaluación de la resistencia in vivo a los medicamentos antimaláricos. El Bagre, Antioquia, 1998. Rev Epidem Antioquia. 1999;24(3-4):181-94.
35. Wernsdorfer WH. Epidemiology of drug resistance in malaria. Acta Trop. 1994;56(2-3):143-56.
36. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg. 2001;65(3):189-92.
37. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. Br Med J. 1996;313(7056):525-8.
38. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996;347(9014):1511-4.
39. McChesney EW, Fasco MJ, Banks WF, Jr. The metabolism of chloroquine in man during and after repeated oral dosage. J Pharmacol Exp Ther. 1967;158(2):323-31.
40. Gustafsson LL, Lindstrom B, Grahnen A, Alvan G. Chloroquine excretion following malaria prophylaxis. Br J Clin Pharmacol. 1987;24(2):221-4.
41. Salako LA, Walker O, Iyun AO. Pharmacokinetics of chloroquine in renal insufficiency. Afr J Med Med Sci. 1984;13(3-4):177-82.
42. Walker O, Salako LA, Alvan G, Ericsson O, Sjoqvist F. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol. 1987; 23(3):295-301.
43. Salako LA, Aderounmu AF, Walker O. Influence of route of administration on the pharmaco-kinetics of chloroquine and desethylchloroquine. Bull World Health Organ. 1987;65(1):47-50.
44. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27(6):771-9.
45. Na-Bangchang K, Limpaibul L, Thanavibul A, Tan-ariya P, Karbwang J. The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol. 1994;38(3):278-81.
46. Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol. 1987;23(1):1-7.
47. Na-Bangchang K, Molunto P, Banmairuroi V, Thanavibul A, Karbwang J. Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. Int J Clin Pharmacol Res. 1995;15(5-6):215-20.
48. Jamaludin A, Mohamad M, Navaratnam V, Yeoh PY, Wernsdorfer WH. Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride. Trop Med Parasitol. 1990;41(3):268-72.
49. White NJ, Watt G, Bergqvist Y, Njelesani EK. Parenteral chloroquine for treating falciparum malaria. J Infect Dis. 1987;155(2):192-201.
50. Winstanley PA, Simooya O, Kofi-Ekue JM, Walker O, Salako LA, Edwards G, et al. The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol. 1990;29(6):695-701.
51. Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, et al. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther. 1999;66(5):472-84.
52. Basco LK, Tahar R, Ringwald P. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother. 1998;42(7):1811-4.
53. Kaneko A, Bergqvist Y, Takechi M, Kalkoa M, Kaneko O, Kobayakawa T, et al. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J Infect Dis. 1999;179(4):974-9.
54. Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, et al. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005;61:15-8.
55. Guengerich FP, Parikh A, Yun CH, Kim D, Nakamura K, Notley LM, et al. What makes P450s work? Searches for answers with known and new P450s. Drug Metab Rev. 2000;32(3-4):267-81.
56. Murray M. Induction and inhibition of CYPs and implications for medicine. Mol Aspects Med. 1999;20(1-2):24-137.
57. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356(9242):1667-71.
58. Ingelman-Sundberg M, Daly AK, Nebert DW. Nomenclature files for human cytochrome P-450 alleles. [Sitio en internet] Page of the Human Cytochrome P-450 (CYP) Allele Nomenclature Committee. Hallado en: http://www.imm.ki.se/ CYPalleles/. Acceso el 31 de agosto de 2005.
59. Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase, cytochrome P-450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol. 1999;29(1):59-124.
60. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11(7):597-607.
61. García-Martín E, Martínez C, Ladero JM, Gamito FJ, Agúndez JA. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol. 2001;57(1):47-9.
62. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A. Malaria eradication on islands. Lancet. 2000;356(9241):1560-4.
63. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther. 2000;68(4):401-11.
64. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos. 2001;29(3):207-12.
65. Cheng PY, Morgan ET. Hepatic cytochrome P-450 regulation in disease states. Curr Drug Metab. 2001;2(2):165-83.
66. Uhl K, Grace JM, Kocisko DA, Jennings BT, Mitchell AL, Brewer TG. Effects of Plasmodium berghei infection on cytochromes P-450 2E1 and 3A2. Eur J Drug Metab Pharmacokinet. 1999;24(2):169-76.
67. Srivastava P, Pandey VC. Studies on hepatic mitochondrial cytochrome P-450 during Plasmodium yoelii infection and pyrimethamine treatment in mice. Ecotoxicol Environ Saf. 2000;46(1):19-22.
68. Srivastava P, Sharma SN, Shukla OP, Pandey VC. Studies of the hepatic mitochondrial and microsomal mixed-function oxidase system during Plasmodium yoelii infection and inducer treatment in Swiss albino mice. Trop Med Int Health. 1997;2(10):989-92.
69. Srivastava P, Pandey VC. Heme oxygenase and related indices in chloroquine-resistant and -sensitive strains of Plasmodium berghei. Int J Parasitol. 1995;25(9):1061-4.
70. Srivastava P, Puri SK, Dutta GP, Pandey VC. Effect of chloroquine on hepatic hemeoxygenase during Plasmodium berghei infection in mice. Int J Parasitol. 1993;23(2):231-4.
71. Srivastava P, Tripathi LM, Puri SK, Dutta GP, Pandey VC. Effect of Plasmodium berghei infection and chloroquine on the hepatic drug metabolizing system of mice. Int J Parasitol. 1991;21(4):463-6.
72. Ismail S, Kokwaro GO, Back DJ, Edwards G. Effect of malaria infection on the pharmacokinetics of paracetamol in rat. Xenobiotica. 1994;24(6):527-33.
73. Glazier AP, Kokwaro GO, Ismail S, Edwards G. Effect of an experimental malaria infection on the metabolism of phenacetin in the rat isolated perfused liver. Xenobiotica. 1994;24(8):785-93.
74. Kokwaro GO, Szwandt IS, Glazier AP, Ward SA, Edwards G. Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. Xenobiotica. 1993;23(12):1391-7.
75. Kokwaro GO, Ismail S, Glazier AP, Ward SA, Edwards G. Effect of malaria infection and endotoxin-induced fever on the metabolism of antipyrine and metronidazole in the rat. Biochem Pharmacol. 1993;45(6):1243-9.
76. Mansor SM, Edwards G, Roberts PJ, Ward SA. The effect of malaria infection on paracetamol disposition in the rat. Biochem Pharmacol. 1991;41(11):1707-11.
77. Mansor SM, Ward SA, Edwards G. The effect of malaria infection on antipyrine metabolite formation in the rat. Biochem Pharmacol. 1991;41(8):1264-6.
78. Mansor SM, Ward SA, Edwards G, Hoaksey PE, Breckenridge AM. The effect of malaria infection on the disposition of quinine and quinidine in the rat isolated perfused liver preparation. J Pharm Pharmacol. 1990;42(6):428-32.
79. Mihaly GW, Date NM, Ireton HJ, Smallwood RA. The effect of malaria infection on primaquine elimination in the isolated perfused rat liver. Biochem Pharmacol. 1987;36(2):225-8.
80. Saxena N, Saxena A, Dutta GP, Ghatak S, Pandey VC. Effect of Plasmodium yoelii nigeriensis infection and chloroquine on the hepatic mixed function oxidase system of mice. Mol Biochem Parasitol. 1987;24(3):283-7.
81. Álvares AP, Ueng TH, Scheibel LW, Hollingdale MR. Impairment of hepatic cytochrome P-450-dependent monooxygenases by the malaria parasite Plasmodium berghei. Mol Biochem Parasitol. 1984;13(3):277-82.
82. McKindley DS, Boulet J, Sachdeva K, Wang P, Chichester C. Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide. Shock. 2002;17(3):199-204.
83. McKindley DS, Chichester C, Raymond R. Effect of endotoxin shock on the clearance of lidocaine and indocyanine green in the perfused rat liver. Shock. 1999;12(6):468-72.
84. Mihaly GW, Date NM, Veenendaal JR, Newman KT, Smallwood RA. Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. Biochem Pharmacol. 1987;36(17):2827-9.
85. Funseth E, Pahlman M, Eloranta ML, Friman G, Ilback NG. Effects of coxsackievirus B3 infection on the acute-phase protein metallothionein and on cytochrome P-4501A1 involved in the detoxification processes of TCDD in the mouse. Sci Total Environ. 2002;284(1-3):37-47.
86. McCarthy JS, Furner RL, Van Dyke K, Stitzel RE. Effects of malarial infection on host microsomal drug-metabolizing enzymes. Biochem Pharmacol. 1970;19(4):1341-9.
87. Srivastava P, Puri SK, Pandey VC. Effect of Plasmodium berghei infection and antimalarial treatment on heme synthesis in mice. Int J Parasitol. 1994;24(5):677-9.
88. Hirano Y, Mizutani T. Study of inhibition of CYP2A6 by some drugs derived from quinoline. J Pharm Pharmacol. 2003;55(12):1667-72.
89. Simooya OO, Sijumbil G, Lennard MS, Tucker GT. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998;45(3):315-7.
90. Ndifor AM, Howells RE, Bray PG, Ngu JL, Ward SA. Enhancement of drug susceptibility in Plasmodium falciparum in vitro and Plasmodium berghei in vivo by mixed-function oxidase inhibitors. Antimicrob Agents Chemother. 1993;37(6):1318-23.
91. Ndifor AM, Ward SA, Howells RE. Cytochrome P-450 activity in malarial parasites and its possible relationship to chloroquine resistance. Mol Biochem Parasitol. 1990;41(2):251-7.
92. Surolia N, Karthikeyan G, Padmanaban G. Involvement of cytochrome P-450 in conferring chloroquine resistance to the malarial parasite Plasmodium falciparum. Biochem Biophys Res Commun. 1993;197(2):562-9.
93. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P-450 2C8. J Clin Pharmacol. 2005;45(1):68-78.
94. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet. 1996;31(1):47-64.
95. Anderson KE, Conney AH, Kappas A. Nutritional influences on chemical biotransformations in humans. Nutr Rev. 1982;40(6):161-71.
96. Guengerich FP. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr. 1995;61(Suppl3): 651S-8S.
97. Campbell TC, Hayes JR. The effect of quantity and quality of dietary protein on drug metabolism. Fed Proc. 1976;35(13):2470-4.
98. Yoo JS, Hong JY, Ning SM, Yang CS. Roles of dietary corn oil in the regulation of cytochromes P-450 and glutathione S-transferases in rat liver. J Nutr. 1990;120(12):1718-26.
99. Yoo JS, Ning SM, Pantuck CB, Pantuck EJ, Yang CS. Regulation of hepatic microsomal cytochrome P450IIE1 level by dietary lipids and carbohydrates in rats. J Nutr. 1991;121(7): 959-65.
100. Murray M, Sefton RM, Croft KD, Butler AM. Differential regulation of endobiotic-oxidizing cytochromes P-450 in vitamin A-deficient male rat liver. Br J Pharmacol. 2001;134(7):1487-97.
101. Yang CS, Yoo JS. Dietary effects on drug metabolism by the mixed-function oxidase system. Pharmacol Ther. 1988;38(1):53-72.
102. Bidlack WR, Brown RC, Mohan C. Nutritional parameters that alter hepatic drug metabolism, conjugation, and toxicity. Fed Proc. 1986;45(2):142-8.
103. Yang CS. Alterations of the aryl hydrocarbon hydroxylase system during riboflavin depletion and repletion. Arch Biochem Biophys. 1974;160(2):623-30.
104. Traber MG. Vitamin E, nuclear receptors and xenobiotic metabolism. Arch Biochem Biophys. 2004;423(1):6-11.
105. Pascoe GA, Sakai-Wong J, Soliven E, Correia MA. Regulation of intestinal cytochrome P-450 and heme by dietary nutrients. Critical role of selenium. Biochem Pharmacol. 1983; 32(20):3027-35.
106. Pascoe GA, Correia MA. Structural and functional assembly of rat intestinal cytochrome P-450 isozymes. Effects of dietary iron and selenium. Biochem Pharmacol. 1985;34(5):599-608.
107. Xu Z, Kawai M, Bandiera SM, Chang TK. Influence of dietary zinc deficiency during development on hepatic CYP2C11, CYP2C12, CYP3A2, CYP3A9, and CYP3A18 expression in postpubertal male rats. Biochem Pharmacol. 2001;62(9):1283-91.
108. Om AS, Chung KW. Dietary zinc deficiency alters 5-alpha-reduction and aromatization of testosterone and androgen and estrogen receptors in rat liver. J Nutr. 1996;126(4):842-8.
109. Koski KG, Scott ME. Gastrointestinal nematodes, nutrition and immunity: breaking the negative spiral. Annu Rev Nutr. 2001;21:297-321.
110. Blair S, Álvarez G, Villa Andrés, Carmona J, Osorio R. Estado nutricional y niveles de inmunoglobulinas y citocinas en niños con malaria. An Pediatr. 2003;58(5):418-24.